Extending (Q)SARs to incorporate proprietary knowledge for regulatory purposes: A case study using aromatic amine mutagenicity.

Journal: Regulatory toxicology and pharmacology : RTP
Published Date:

Abstract

Statistical-based and expert rule-based models built using public domain mutagenicity knowledge and data are routinely used for computational (Q)SAR assessments of pharmaceutical impurities in line with the approach recommended in the ICH M7 guideline. Knowledge from proprietary corporate mutagenicity databases could be used to increase the predictive performance for selected chemical classes as well as expand the applicability domain of these (Q)SAR models. This paper outlines a mechanism for sharing knowledge without the release of proprietary data. Primary aromatic amine mutagenicity was selected as a case study because this chemical class is often encountered in pharmaceutical impurity analysis and mutagenicity of aromatic amines is currently difficult to predict. As part of this analysis, a series of aromatic amine substructures were defined and the number of mutagenic and non-mutagenic examples for each chemical substructure calculated across a series of public and proprietary mutagenicity databases. This information was pooled across all sources to identify structural classes that activate or deactivate aromatic amine mutagenicity. This structure activity knowledge, in combination with newly released primary aromatic amine data, was incorporated into Leadscope's expert rule-based and statistical-based (Q)SAR models where increased predictive performance was demonstrated.

Authors

  • Ernst Ahlberg
    AstraZeneca, Mölndal, Sweden.
  • Alexander Amberg
    Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
  • Lisa D Beilke
    Toxicology Solutions, San Diego, CA, USA.
  • David Bower
    Leadscope, Columbus, OH, USA.
  • Kevin P Cross
    Leadscope, Columbus, OH, USA.
  • Laura Custer
    Bristol-Myers Squibb Co., New Brunswick, NJ, USA.
  • Kevin A Ford
    Genentech, South San Francisco, USA.
  • Jacky Van Gompel
    Janssen Research and Development, Beerse, Belgium.
  • James Harvey
    GlaxoSmithKline, Ware, UK.
  • Masamitsu Honma
    National Institute of Health Sciences, Tokyo, Japan.
  • Robert Jolly
    Eli Lilly and Company, Indianapolis, IN, USA.
  • Elisabeth Joossens
    European Commission Joint Research Centre, Ispra, Italy.
  • Raymond A Kemper
    Vertex, Boston, MA, USA.
  • Michelle Kenyon
    Pfizer, Groton, CT, USA.
  • Naomi Kruhlak
    FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA.
  • Lara Kuhnke
    Bayer HealthCare, Berlin, Germany.
  • Penny Leavitt
    Bristol-Myers Squibb Co., New Brunswick, NJ, USA.
  • Russell Naven
    Pfizer, Groton, CT, USA.
  • Claire Neilan
    Incyte Corporation, Wilmington, DE, USA.
  • Donald P Quigley
    Leadscope, Columbus, OH, USA.
  • Dana Shuey
    Incyte Corporation, Wilmington, DE, USA.
  • Hans-Peter Spirkl
    Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany.
  • Lidiya Stavitskaya
    FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA.
  • Andrew Teasdale
    AstraZeneca, Cheshire, England, UK.
  • Angela White
    GlaxoSmithKline, Ware, UK.
  • Joerg Wichard
    Bayer HealthCare, Berlin, Germany.
  • Craig Zwickl
    Eli Lilly and Company, Indianapolis, IN, USA.
  • Glenn J Myatt
    Instem, Diamond Way, Stone Business Park, Stone, Staffordshire, ST150SD, United Kingdom.